CGTs Prompt More Attention on Fertility Services Benefits

Jul 17
Jul 17, 2025

People who undergo treatment with cell and gene therapies (CGTs) face a long, complex and often grueling process, from sickness to diagnosis to pretreatment requirements to the treatment itself to post-treatment monitoring and follow up. On top of all that, many people must grapple with a consideration that for some means walking away from treatment: the loss of fertility.

Before people can be treated with many of the available CGTs, they must undergo myeloablative conditioning, which involves being administered high doses of chemotherapy or radiation to destroy their bone marrow in order to cut down on the chance of their immune system rejecting the new cells. Unfortunately, infertility very often is a complication of this process, which may be a reason for people to not undergo treatment.
Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.